Katie Tyson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katie Tyson has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Iain A. McNeish
Department of Surgery and Cancer, Imperial College London, London, UK
24 shared publications - Hasan Mirza
Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
20 shared publications - Hector Charles Keun
Imperial College London
20 shared publications - Sarah Spear
Division of Cancer, Department of Surgery and Cancer, Imperial College London
20 shared publications - Yuewei Xu
Department of Surgery & Cancer, Imperial College London; London, UK
20 shared publications - Ana P. Costa Pereira
Department of Biochemistry, University College, Ireland
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure legends from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Legends to supplementary figures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure legends from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Legends to supplementary figures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 Genes per cluster from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Genes upregulated in each mouse macrophage cluster
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 Genes per cluster from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Genes upregulated in each mouse macrophage cluster
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 HMOX1-hi gene expression from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Up- and down-regulated differentially expressed genes in HMOX1-hi human macrophages
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 HMOX1-hi gene expression from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Up- and down-regulated differentially expressed genes in HMOX1-hi human macrophages
- Top Cited PapersOpen Access
- 24 April 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (5) , 915-929
Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability
Senescent cells drive ageing and age-related pathologies, including cancer. Consequently, senolytics, drugs that selectively kill senescent cells, have broad therapeutic appeal. Here we report a senolytic screen of a library of 10,480 electrophilic compounds. Among 38 identified hits, we found a subset of chloroacetamides with broad senolytic activity. Activity-based protein profiling, coupled with functional assays, identified the glutathione peroxidase GPX4 as a target. We show that senescent cells are primed for ferroptosis, displaying high levels of oxidative stress and intracellular Fe 2+ , but also upregulate GPX4, which prevents the accumulation of oxidized lipids. Treatment with senolytic chloroacetamides or GPX4 inhibitors selectively kills senescent cells by ferroptosis. The combination of anticancer therapies with GPX4 inhibitors eliminated senescent tumour cells in models of melanoma, prostate and ovarian cancer. Our results show that senescent cells rely on GPX4 to prevent ferroptosis and that GPX4 inhibitors kill senescent cells.
- 24 April 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (5) , 915-929
Top Cited PapersOpen AccessElectrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability
Senescent cells drive ageing and age-related pathologies, including cancer. Consequently, senolytics, drugs that selectively kill senescent cells, have broad therapeutic appeal. Here we report a senolytic screen of a library of 10,480 electrophilic compounds. Among 38 identified hits, we found a subset of chloroacetamides with broad senolytic activity. Activity-based protein profiling, coupled with functional assays, identified the glutathione peroxidase GPX4 as a target. We show that senescent cells are primed for ferroptosis, displaying high levels of oxidative stress and intracellular Fe 2+ , but also upregulate GPX4, which prevents the accumulation of oxidized lipids. Treatment with senolytic chloroacetamides or GPX4 inhibitors selectively kills senescent cells by ferroptosis. The combination of anticancer therapies with GPX4 inhibitors eliminated senescent tumour cells in models of melanoma, prostate and ovarian cancer. Our results show that senescent cells rely on GPX4 to prevent ferroptosis and that GPX4 inhibitors kill senescent cells.
- Open Access
- 17 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors
For all drugs, effective target engagement requires sufficient intracellular concentrations of drug to be reached, but whether tumour heterogeneity impacts drug distribution and efficacy is poorly studied. Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed treatment opportunities for women with high-grade serous ovarian carcinoma, but resistance remains a clinical hurdle in this highly heterogeneous tumour type. Here, we present a patient-derived explant multi-modal imaging pipeline, which demonstrates that cell-intrinsic PARP inhibitor accumulation is highly variable, both between patients and within tumours. Spatial transcriptomics reveals enrichment of apoptotic and lysosomal signatures in high-drug regions. Rucaparib, an intrinsically fluorescent PARP inhibitor, accumulates heterogeneously at the single-cell level, with rucaparib-high cells demonstrating increased drug response relative to rucaparib-low. Mechanistically, lysosomal sequestration creates a rucaparib reservoir that determines drug levels in the nucleus. Perturbation of lysosomal content alters intracellular levels of weak base PARP inhibitors rucaparib and niraparib, but not olaparib. Together these data suggest that lysosomes act as a reservoir for a subset of PARP inhibitor drugs to improve drug response.
- 17 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMultimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors
For all drugs, effective target engagement requires sufficient intracellular concentrations of drug to be reached, but whether tumour heterogeneity impacts drug distribution and efficacy is poorly studied. Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed treatment opportunities for women with high-grade serous ovarian carcinoma, but resistance remains a clinical hurdle in this highly heterogeneous tumour type. Here, we present a patient-derived explant multi-modal imaging pipeline, which demonstrates that cell-intrinsic PARP inhibitor accumulation is highly variable, both between patients and within tumours. Spatial transcriptomics reveals enrichment of apoptotic and lysosomal signatures in high-drug regions. Rucaparib, an intrinsically fluorescent PARP inhibitor, accumulates heterogeneously at the single-cell level, with rucaparib-high cells demonstrating increased drug response relative to rucaparib-low. Mechanistically, lysosomal sequestration creates a rucaparib reservoir that determines drug levels in the nucleus. Perturbation of lysosomal content alters intracellular levels of weak base PARP inhibitors rucaparib and niraparib, but not olaparib. Together these data suggest that lysosomes act as a reservoir for a subset of PARP inhibitor drugs to improve drug response.
- Open Access
Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionised the treatment of ovarian high grade serous carcinoma (HGSC), especially those with defective homologous recombination. However, the emergence of resistance poses a critical challenge, as over 50% of patients relapse within three years. The mechanisms underlying changes in PARP trapping, a central aspect of PARPi efficacy, are not well understood due to limitations in current experimental methodologies. Existing techniques lack resolution and throughput, impeding efforts to study PARP trapping dynamics over time with single-cell resolution. Effective tools to study PARP trapping in live cells are urgently needed to elucidate resistance mechanisms and inform therapeutic strategies. To address this, we used CRISPR-Cas9 gene editing to dual-label endogenous PARP1 with EGFP and mCherryFP in OVCAR4 cells to develop a novel intramolecular FRET-based biosensor that enables real-time, single-cell visualization of PARP trapping dynamics in live cells. High-content fluorescence lifetime imaging microscopy (FLIM) revealed dose dependent PARP trapping upon exposure to PARP inhibitor and distinguished between the trapping efficiencies of four different PARPi (veliparib, olaparib, rucaparib, talazoparib). Moreover, we found reduced PARP trapping in PARPi-resistant models, both in vitro and in vivo , providing critical evidence for altered PARP trapping as a resistance mechanism and illustrating the potential of this FRET biosensor to interrogate resistance mechanisms quantitatively. This PARP trapping biosensor represents a transformative advance, enabling dynamic, high-resolution analysis of mechanisms underlying cancer drug resistance. It provides critical insights into the heterogeneity of PARPi resistance, with implications for developing more effective therapies and improving personalised treatment strategies for ovarian cancer patients. Graphical
Open AccessAssessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionised the treatment of ovarian high grade serous carcinoma (HGSC), especially those with defective homologous recombination. However, the emergence of resistance poses a critical challenge, as over 50% of patients relapse within three years. The mechanisms underlying changes in PARP trapping, a central aspect of PARPi efficacy, are not well understood due to limitations in current experimental methodologies. Existing techniques lack resolution and throughput, impeding efforts to study PARP trapping dynamics over time with single-cell resolution. Effective tools to study PARP trapping in live cells are urgently needed to elucidate resistance mechanisms and inform therapeutic strategies. To address this, we used CRISPR-Cas9 gene editing to dual-label endogenous PARP1 with EGFP and mCherryFP in OVCAR4 cells to develop a novel intramolecular FRET-based biosensor that enables real-time, single-cell visualization of PARP trapping dynamics in live cells. High-content fluorescence lifetime imaging microscopy (FLIM) revealed dose dependent PARP trapping upon exposure to PARP inhibitor and distinguished between the trapping efficiencies of four different PARPi (veliparib, olaparib, rucaparib, talazoparib). Moreover, we found reduced PARP trapping in PARPi-resistant models, both in vitro and in vivo , providing critical evidence for altered PARP trapping as a resistance mechanism and illustrating the potential of this FRET biosensor to interrogate resistance mechanisms quantitatively. This PARP trapping biosensor represents a transformative advance, enabling dynamic, high-resolution analysis of mechanisms underlying cancer drug resistance. It provides critical insights into the heterogeneity of PARPi resistance, with implications for developing more effective therapies and improving personalised treatment strategies for ovarian cancer patients. Graphical
- Open Access
- 17 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (3) , eadn2811
SMARCA4 regulates the NK-mediated killing of senescent cells
Induction of senescence by chemotherapeutic agents arrests cancer cells and activates immune surveillance responses to contribute to therapy outcomes. In this investigation, we searched for ways to enhance the NK-mediated elimination of senescent cells. We used a staggered screen approach, first identifying siRNAs potentiating the secretion of immunomodulatory cytokines to later test for their ability to enhance NK-mediated killing of senescent cells. We identified that genetic or pharmacological inhibition of SMARCA4 enhanced senescent cell elimination by NK cells. SMARCA4 expression is elevated during senescence and its inhibition derepresses repetitive elements, inducing the SASP via activation of cGAS/STING and MAVS/MDA5 pathways. Moreover, a PROTAC targeting SMARCA4 synergized with cisplatin to increase the infiltration of CD8 T cells and mature, activated NK cells in an immunocompetent model of ovarian cancer. Our results indicate that SMARCA4 inhibitors enhance NK-mediated surveillance of senescent cells and may represent senotherapeutic interventions for ovarian cancer.
- 17 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (3) , eadn2811
Open AccessSMARCA4 regulates the NK-mediated killing of senescent cells
Induction of senescence by chemotherapeutic agents arrests cancer cells and activates immune surveillance responses to contribute to therapy outcomes. In this investigation, we searched for ways to enhance the NK-mediated elimination of senescent cells. We used a staggered screen approach, first identifying siRNAs potentiating the secretion of immunomodulatory cytokines to later test for their ability to enhance NK-mediated killing of senescent cells. We identified that genetic or pharmacological inhibition of SMARCA4 enhanced senescent cell elimination by NK cells. SMARCA4 expression is elevated during senescence and its inhibition derepresses repetitive elements, inducing the SASP via activation of cGAS/STING and MAVS/MDA5 pathways. Moreover, a PROTAC targeting SMARCA4 synergized with cisplatin to increase the infiltration of CD8 T cells and mature, activated NK cells in an immunocompetent model of ovarian cancer. Our results indicate that SMARCA4 inhibitors enhance NK-mediated surveillance of senescent cells and may represent senotherapeutic interventions for ovarian cancer.